in humans and TRAV1-TRAJ33 in mice) coupled with a limited repertoire of β-chains. This endows them with the ability to recognize bacteria-derived precursors of riboflavin presented by the major-histocompatibilitycomplex-class-I-related protein MR1 (ref. 5 ). The development of MAIT cells is impaired in germ-free mice 6 , which emphasizes the intimate connection between these cells and commensal microflora.
To probe the possible involvement of MAIT cells in T1D, Rouxel et al. first assess their number in the peripheral blood of children who had developed T1D within the preceding 10 days ('recent-onset T1D') 1 . They find that the frequency of MAIT cells is significantly lower in those children than in age-matched control children (with disorders unrelated to diabetes). The phenotype of MAIT cells in children with recent-onset T1D is also distinct, with higher expression of the activation and/or exhaustion markers CD25 and PD-1 and lower expression of the tissue-recruitment and/or adhesion molecules CCR6 and CD56 than that of such cells from control children. In addition, MAIT cells obtained from children with recent-onset T1D and stimulated with the phorbol ester PMA and ionomycin produce less of the cytokine IFN-γ but more of the cytokines TNF and IL-4 and the serine protease granzyme B than do their counterparts from control children.
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The authors declare competing financial interests: details are available in the online version of the paper. pharmacological or dietary intervention. If such a systemic decrease in the levels of aromatic amino acids occurs in humans as well, under conditions of immune-system stimulation, it might account for behavioral changes such as anxiety, depression and chronic fatigue during inflammatory diseases. It will be important to determine whether dietary supplementation with amino acids or pharmacological intervention might be required as part of the support treatment for patients fighting infections, flareups of autoimmune diseases or undergoing cancer immunotherapy, to prevent effects on the CNS. It might also be beneficial to determine whether depletion of aromatic amino acids during cancer immunotherapy can be detected in patients' serum and, if so, whether it might be used as a tentative biomarker indicative of antitumor T cell responses.
Growing evidence suggests that not only immunotherapy but also targeted agents and chemotherapies require an endogenous immune response to induce tumor regression 12 . Any type of cancer therapy could potentially result in systemic metabolic changes due to immune-system-mediated metabolic reprogramming of T cells, which might directly affect the nervous system. Thus, the link between the CNS and the immune system, particularly in the context of cancer, might be bidirectional. It is not only the nervous system, through catecholamines and adrenergic signaling, that can modulate and impair the function of cells that are critical for anti-tumor immune responses and promote cancer-cell survival 1 , but also the activated immune cells that can impair the function of the CNS by depleting neurotransmitters that regulate executive functions.
MAIT cells in type 1 diabetes: a good friend turned bad
Lina Petersone & Lucy S K Walker
Mucosal-associated invariant T cells (MAIT cells) normally preserve gut-barrier integrity but can switch their phenotype to have a pathogenic role in type 1 diabetes.
T he iterative dialog between gut microbiota and the immune system has emerged as a dominant theme in immunological research, but how microbial cues shape the development of immune-system-mediated disease has remained unclear. In this issue of Nature Immunology, Rouxel et al. suggest that mucosal-associated invariant T cells (MAIT cells) responding to microbial metabolites can influence the development of type 1 diabetes (T1D) 1 .
T1D is a complex autoimmune disease that leads to the destruction of insulinproducing pancreatic β-cells and a requirement for lifelong administration of exogenous insulin 2 . While the pathophysiology of T1D is still not entirely understood, a growing body of evidence indicates that alterations in gut permeability and changes to the intestinal microbiota can occur early in disease development 3, 4 . MAIT cells are innate-like T cells that are abundant in the intestine; they express a T cell antigen receptor composed of an invariant α-chain (TRAV1-2-TRAJ33/12/20
Remarkably, measurement of just four markers (CCR6, CD25, PD-1 and CD56) on MAIT cells in the blood is sufficient to define a predictive diagnostic model capable of distinguishing the newly diabetic children from control children.
Curiously, the authors identify a relationship between the expression of granzyme B by MAIT cells and age at T1D diagnosis, with a young age at diagnosis being associated with a high frequency of granzyme B-positive MAIT cells. This is interesting, given the growing recognition that children diagnosed at a young age appear to exhibit a more-aggressive disease course and have fewer insulin-expressing pancreatic islets at diagnosis 7 . Spurred on by this finding, the authors begin to wonder whether MAIT cells can use their cytotoxic potential to directly contribute to pancreatic β-cell death. Staging the 'perfect crime scene' , they co-culture purified MAIT cells with the human β-cell line EndoC-βH1, throwing in the MAIT-cell ligand 5-OP-RU to initiate interactions. However, the anticipated killing spree never materializes. Mindful that surface levels of MR1 are low on most cell types 8 , the authors add inflammatory cytokines into the mix, opting for IL-1β, IFN-γ and TNF, since these are typically present in inflamed islets in the T1D setting. Strikingly, MR1 expression on the EndoC-βH1 cells increases and the MAIT cells become activated and degranulated, eliciting volume 18 number 12 DeCember 2017 nature immunology in IL-23 in the ileum at the onset of diabetes, which could explain the drop in the production of IL-22 and IL-17 by MAIT cells. Intriguingly, this coincides with an increase in gut permeability, as assessed by the level of fluorescein isothiocyanate-dextran in the blood after oral gavage, which raises the possibility that alterations to MAIT cells are 'instructed' by microbederived ligands.
To directly investigate the role of MAIT cells in diabetes pathogenesis, the authors painstakingly generate Mr1 -/-NOD mice and compare them with co-housed Mr1 +/-littermates, to avoid differences in gut microbiota. The lack of MAIT cells in the absence of MR1 leads to a severely damaged gut epithelium, increased intestinal permeability and greater activation of the immune system, which results in significantly exacerbated disease. These data reveal a protective role for MAIT cells in the development of T1D linked to their ability to maintain gut integrity. They also indicate (unsurprisingly) that MAIT cells are not absolutely required for islet destruction or for sensing the loss of gut-barrier integrity, even though they might contribute to these processes.
One question that arises from these studies echoes the classic chicken-and-egg conundrum: does impaired MAIT-cell function trigger loss of gut integrity, or does a leaky gut stimulate MAIT-cell changes? Given the 'smorgasbord' of susceptibility loci that influence real-world autoimmunity, it is easy to envisage that both scenarios might exist, with some people having single-nucleotide polymorphisms that alter the activation and/or homing of MAIT cells and others being genetically predisposed killing dependent on ligand dose and blocked by antibody to MR1. Further work is needed to determine whether MAIT cells are present at the 'scene of the crime' in the pancreas of diabetic humans and whether primary β-cells can indeed express MR1 in situ. Nevertheless, these provocative findings suggest the potential for MAIT cells to directly participate in the process of β-cell destruction (Fig. 1) .
In mice, MAIT cells constitute only ~0.1% of peripheral blood T cells, compared with ~6% in humans 9 , and until recently, the study of mouse MAIT cells was limited by a lack of sensitive identification methods. However, the development of MR1 tetramers loaded with the riboflavin derivative 5-OP-RU has allowed researchers to recapitulate in mouse models many of the observations previously made with human MAIT cells 9 . Taking advantage of this research tool, Rouxel et al. turn to the non-obese diabetic (NOD) mouse model of T1D 1 . They find that in general, the frequency of MAIT cells is lower in NOD mice than in the C57BL/6 mice used as a control and is even below detection levels in the blood. Interestingly, however, MAIT cells are present in the pancreatic islets of NOD mice and are more abundant in the ileum of NOD mice than in that of C57BL/6 mice.
One limitation of human studies is the understandable reliance on peripheral-blood samples and the inability to simultaneously explore multiple tissue sites. Taking advantage of the mouse model, Rouxel et al. are able to gain a more comprehensive view of how MAIT cells redistribute during disease development 1 . Interestingly, progression to diabetes in NOD mice is associated with a trend toward a lower frequency of MAIT cells in the ileum and spleen and a concomitant increase in their frequency in the pancreatic lymph nodes and pancreatic islets. Adoptive-transfer experiments confirm that MAIT cells are able to migrate directly from the blood to the tissues, with a strong 'preference' for the ileum rather than islets in young NOD mice but a shift toward migration to the islets in older mice.
Most interesting is the change in MAITcell phenotype during disease progression. In 16-week-old mice, islet-resident MAIT cells already express some granzyme B, but in diabetic mice, its expression is much higher and IFN-γ is also produced. Conversely, in the ileum, MAIT cells produce IL-22 and IL-17 in 16-week-old mice, but this is almost completely extinguished in diabetic mice. These kinetic data capture the shift in the 'behavior' of MAIT cells as they forsake their role in gut homeostasis to join the conventional T cells waging war in the islets. So what is the trigger for this shift? The authors note a decrease to increased gut permeability. Deeper understanding of MAIT-cell biology could potentially shed light on the association between T1D and celiac disease, given the link to gut permeability in both conditions.
Arguably the most notable finding of the study is that MAIT-cell changes can be detected in humans even before the development of diabetes. Accordingly, relatives of people with T1D with at least two autoantibodies have blood MAIT cells with phenotypic alterations similar to those seen in the patients with newly onset T1D. Since risk profiles differ for relatives with a single autoantibody versus those with multiple autoantibodies, it would be of great interest to compare the MAIT-cell phenotypes of these groups and assess the relationship with disease progression. Perhaps tracking MAIT cells can help discern which people in the 'atrisk' category will go on to develop disease.
More generally, the findings add to a growing body of work highlighting environmental influences on autoimmune-disease development. Over the past few decades, the incidence of T1D has increased dramatically at a rate that suggests the involvement of factors beyond genetic changes. At the same time, it has become apparent that the immune system is shaped to a surprising extent by non-heritable influences 10 . The microbiota undoubtedly exerts a major influence on immunity, with suggestions that bacteria can even translocate from the gut to the pancreatic lymph nodes in a mouse model of diabetes 11 . The new findings from Rouxel et al. 1 position MAIT cells at the nexus between microbiota and immunological function, limiting commensal (Fig. 1) . Among those mechanisms, the suppression of APCs by CTLA-4 (which is constitutively expressed by T reg cells) and consumption of IL-2 via CD25 (the IL-2 receptor α-chain, which also has constitutively high expression by T reg cells) have been thought to serve key roles in the suppressive function of T reg cells 1 . In particular, CTLA-4 on T reg cells engages the costimulatory ligands CD80 and CD86 on APCs with higher binding affinity than does CD28 (a crucial co-stimulatory receptor for optimal activation of T cells) 7 and inhibits APCs, which stops the further activation of effector T cells. Since CTLA-4 on T reg cells exhibits suppressive activity in an antigen-specific manner with APCs, antibodies to CTLA-4 can target T reg cells in the tumor microenvironment, which results in tumor regression, an effect seen in patients with melanoma who show a partial response after treatment with ipilimumab, a monoclonal antibody to CTLA-4 (ref. 8) .
Although infiltration of T reg cells with strong immunosuppressive function is detected in tumor microenvironments, this is somewhat paradoxical due to the fact that the microenvironment is relatively starved of nutrients, especially of glucose, which is required for T cell activity. One plausible explanation is that effector T cells and T reg cells utilize distinct metabolic programs for their functions of glycolysis and lipid oxidation, which depend on the metabolic checkpoint kinase mTOR and the kinase AMPK, respectively. T reg cells are able to survive and function in tumor microenvironments with a low glucose supply 9, 10 . Now Maj et al. demonstrate that adenosine produced by apoptotic T reg cells has a more important suppressive role in the tumor microenvironment than that of live T reg cells 6 (Fig. 1) . They find that T reg cells undergo apoptosis as a result of oxidative dissemination by preserving gut integrity and in turn being stimulated by microbial products. Tantalizingly, although MAIT cells recognize bacterial metabolites, emerging evidence suggests that they are also activated during viral infection 12 . Given the putative links between viral infection and T1D, this promises to be an active area of future investigation.
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OXP3 + CD4 + regulatory T cells (T reg cells) have proven roles in the maintenance of self-tolerance in healthy people. Accordingly, T reg cells protect hosts from developing autoimmune diseases and allergies, whereas in malignancies, they hinder immunosurveillance against cancer in healthy people but also hamper the development of effective antitumor immunity in tumor-bearing patients and thus promote tumor progression 1,2 . T reg cells show an increased frequency in tumors, accounting for up to 20-50% of CD4 + T cells, compared with 5-10% in the peripheral blood of healthy people, and their presence helps to establish a suppressive microenvironment that results in a poor prognosis in various types of cancers [3] [4] [5] . T reg cells are therefore recognized as a crucial target for the generation of effective antitumor immunity. In the current issue of Nature Immunology, Maj et al. demonstrate an unexpected mechanism by which T reg cells contribute to the immunosuppressive tumor microenvironment 6 .
T reg cells exert their suppressive activity through several cellular and humoral mechanisms, such as the suppression of antigenpresenting cells (APCs) via the co-inhibitory receptor CTLA-4, consumption of the cytokine IL-2, secretion of inhibitory cytokines (IL-10, TGF-β and IL-35), expression of granzyme stress within the tumor microenvironment, which triggers the release of large amounts of ATP that is in turn converted into adenosine via the T reg cell-expressed ectoenzymes CD39 and CD73. The abundant adenosine thus generated engages purinergic A 2A receptors (A 2A Rs), which results in an immunosuppressive signaling pathway in tumor-infiltrating effector lymphocytes and APCs (Fig. 1) . Unexpectedly, the apoptotic T reg cells do not exert their immunosuppressive function via cell-surface molecules such as CTLA-4 and the immunoinhibitory receptor PD-1 and/or its ligand PD-L1, nor do soluble immunosuppressive factors such as TGF-β, IL-35 and IL-10, seem to be important. Furthermore, apoptotic T reg cells inhibit the spontaneous antitumor activity and treatment effects mediated by blockade of PD-1-PD-L1 and adoptive T cell transfer. These findings suggest the importance of combining strategies to control immunosuppression mediated by apoptotic T reg cellgenerated adenosine.
So far, clinical trials based on depletion of T reg cells have not been fully effective. The study by Maj et al. provides an important clue to successful therapy by blocking the potent suppressive activity of apoptotic T reg cells within the tumor microenvironment 6 . Approaches targeting the adenosine-A 2A R pathway are indeed currently under investigation as a potential cancer immunotherapy 11 , and some clinical trials including combination with blockade of PD-1-PD-L1 are ongoing or are being planned. The results of these trials are greatly anticipated. Maj et al. show that another potent strategy for controlling suppression by T reg cells in tumor microenvironments is through blocking their apoptosis by scavenging reactive oxygen species through the use of N-acetyl-cysteine 6 . The data obtained by Maj et al. also highlight the need
